Ofichem Header Ofichem Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of IRLAB.

    Client Virtual Booth

    IRLAB

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    IRLAB
    Sweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Arvid Wallgrens Backe 20 413 46 Gothenburg, Sweden
    Telephone
    Telephone
    +46(0)31 757 38 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://irlab.se/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/irlab-therapeutics-ab/
    Twitter
    Twitter
    https://twitter.com/IRLABThera

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    IRLAB Strengthens its Liquidity by Drawing SEK 25M on a Previously Secured Loan Facility

    Details:

    The net proceeds will fund company's clinical drug candidates including, IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders.


    Lead Product(s): IRL757

    Therapeutic Area: Neurology Product Name: IRL757

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Fenja Capital

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Financing May 23, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    IRLAB has Administered the First Dose in a Phase I Trial with the Drug Candidate IRL757

    Details:

    IRL757 is a once daily oral tablet which is being investigated in a phase 1 trial to treat patients with apathy in Parkinson’s and other neurological disorders.


    Lead Product(s): IRL757

    Therapeutic Area: Neurology Product Name: IRL757

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 22, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    IRLAB Enters a Development Collaboration for IRL757 as a Novel Treatment for Apathy

    Details:

    IRLAB and MSRD will exclusively collaborate in the development of IRLAB's novel drug candidate IRL757 for the potential treatment of apathy in Parkinson's and other neurological conditions through clinical proof-of-concept.


    Lead Product(s): IRL757

    Therapeutic Area: Neurology Product Name: IRL757

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: McQuade Center

    Deal Size: $8.5 million Upfront Cash: $3.0 million

    Deal Type: Collaboration May 07, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757

    Details:

    IRL757 is a once daily oral tablet which have undergone IND enabling studies and aims to treat apathy in Parkinson’s and other neurological disorders.


    Lead Product(s): IRL757

    Therapeutic Area: Neurology Product Name: IRL757

    Highest Development Status: Phase IProduct Type: Undisclosed

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 06, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    IRLAB Receives Minutes From End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program For Mesdopetam

    Details:

    IRL790 (mesdopetam) is an investigational drug, a dopamine D3 receptor antagonist which is under phase 2 clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesias (PD-LIDs).


    Lead Product(s): Mesdopetam

    Therapeutic Area: Neurology Product Name: IRL790

    Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 22, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    IRLAB has Completed a Successful End-of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam

    Details:

    IRL790 (mesdopetam), a dopamine D3 receptor antagonist, is being developed as a treatment for Parkinson's disease levodopa-induced dyskinesias (PD-LIDs).


    Lead Product(s): Mesdopetam

    Therapeutic Area: Neurology Product Name: IRL790

    Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 22, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    IRLAB’s Pioneering Phase IIb Study with Pirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Dri...

    Details:

    IRL752 (pirepemat) is a first-in-class, small-molecule cortical enhancer & a 5HT7/Alpha-2 receptor antagonist. It is being evaluated in phase 2 clinical trials for the treatment of parkinson disease.


    Lead Product(s): Pirepemat

    Therapeutic Area: Neurology Product Name: IRL752

    Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 06, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    IRLAB is Granted an End-of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program

    Details:

    IRL790 (mesdopetam) is an investigational drug, a dopamine D3 receptor antagonist which is under phase 2 clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesias (PD-LIDs).


    Lead Product(s): Mesdopetam

    Therapeutic Area: Neurology Product Name: IRL790

    Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 02, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    IRLAB Increases its Liquidity with a Loan Facility of Up to SEK 55 Million that Extends Financial Runway and Increases Business Opportunities

    Details:

    The financing will be used for the advancement of IRL790 (mesdopetam), in development for the treatment of levodopa-induced dyskinesias, which has completed Phase IIb and is in preparation toward Phase III.


    Lead Product(s): Mesdopetam

    Therapeutic Area: Neurology Product Name: IRL790

    Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Formue Nord Fokus

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Financing December 22, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    IRLAB’s Drug Candidate IRL757 is Phase I Ready

    Details:

    IRLAB’s drug candidate IRL757 has completed all preclinical studies and development work necessary to start Phase I trial studies. It has shown tremendous potential in this indication in the preclinical program of Parkinson's Disease and other neurological conditions.


    Lead Product(s): IRL757

    Therapeutic Area: Neurology Product Name: IRL757

    Highest Development Status: IND EnablingProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 20, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    lgm-pharma-m-2024-07-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search